Celltrion Challenges Rival Asthma Treatment At Trial
Counsel for Celltrion Inc. kicked off at trial Friday alleging that a patent underpinning rival Genentech's asthma treatment should be nixed, marking the latest in an ongoing global spat over omalizumab....To view the full article, register now.
Already a subscriber? Click here to view full article